Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
about
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismAripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Optimal sampling of antipsychotic medicines: a pharmacometric approach for clinical practice.Immunotoxicological Effects of Aripiprazole: In vivo and In vitro Studies.Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationshipComparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.A review of the safety and tolerability of aripiprazole.Pharmacokinetics and metabolism update for some recent antipsychotics.Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy.Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice: update and report from a pharmacogenetic service clinic.Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse.A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder.
P2860
Q28084069-FD5E4AC9-64AE-4519-8CD4-CDCD4AD20AC2Q33799660-60B5CE0C-81E7-42E7-B7AF-E417A8BC6F7DQ34554423-8C9569F2-7BA3-4305-BC69-71D8F462ABBEQ35843979-FF054622-7BDD-4B75-B0FD-C061F4EDC3E1Q35866868-9720FABD-1D90-44ED-92FF-B23BC535EEEFQ37461978-DC62FA7C-90F9-4D9F-A5E0-4040AD72E7A6Q37510958-EA0A6676-612A-4BA9-82CF-B341E5A64A2DQ37863118-F9540909-4792-42AB-85CE-722A1069E007Q38154911-42D7B21A-6C3D-495A-B626-84FDFD8AF2EEQ38154915-3CFE8DF4-D4AA-4E74-AD21-58E56D8563DAQ41918764-29E2E6BD-8B4C-488E-8991-02EEFE95644AQ52605626-9BCBA92E-A3BF-4148-AADB-C0D963B9A97E
P2860
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@en
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@nl
type
label
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@en
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@nl
prefLabel
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@en
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@nl
P2093
P2860
P1476
Population pharmacokinetic mod ...... zole, in psychiatric patients.
@en
P2093
Do-Hyung Kang
Hyo-Bum Seo
In-Jin Jang
Joo-Youn Cho
Jun Soo Kwon
Jung-Ryul Kim
Kyung-Sang Yu
Sang-Goo Shin
Won-Myong Bahk
Yong Ku Kim
P2860
P304
P356
10.1111/J.1365-2125.2008.03223.X
P407
P577
2008-12-01T00:00:00Z